NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)
Portfolio Pulse from
Ultragenyx Pharmaceutical Inc. announced that NHS England has started commissioning Evkeeza for eligible patients with Homozygous Familial Hypercholesterolaemia, following NICE guidance. The drug will be available in seven hospital trusts in England.
December 20, 2024 | 8:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ultragenyx's Evkeeza has been commissioned by NHS England for patients with HoFH, potentially increasing the drug's market reach and sales.
The commissioning of Evkeeza by NHS England following NICE guidance is a significant regulatory milestone for Ultragenyx. This approval allows the drug to be routinely available in seven hospital trusts, potentially increasing its market penetration and sales in the UK. The news is likely to positively impact Ultragenyx's stock price in the short term as it expands the company's market reach and revenue potential.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90